Cargando…

The eight-year long-term follow-up on the effectiveness of the quadrivalent human papillomavirus vaccine in Chinese women 20-45 years of age

The quadrivalent human papillomavirus (4vHPV) vaccine has shown confirmative effectiveness in preventing HPV-related diseases among women and men around the globe. The phase III, randomized, double-blind efficacy study (Base study, NCT00834106) conducted in China showed 100% efficacy against HPV 16/...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Chao, Zhao, Yun, Li, Jingran, Li, Mingzhu, Su, Yanyan, Mi, Xin, La Tu, Su Yi, Shen, Danhua, Ren, Lihua, Li, Yanyan, Wang, Linhong, Wei, Lihui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	HPV – Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9225595/ https://www.ncbi.nlm.nih.gov/pubmed/35358015 http://dx.doi.org/10.1080/21645515.2022.2052700

Ejemplares similares

Human papillomavirus (HPV) vaccines in adults: Learnings from long-term follow-up of quadrivalent HPV vaccine clinical trials
por: Goldstone, Stephen E.
Publicado: (2023)

Effectiveness, immunogenicity, and safety of the quadrivalent HPV vaccine in women and men aged 27–45 years
por: Maldonado, Ivette, et al.
Publicado: (2022)

Epidemiology of human papillomavirus on condyloma acuminatum in Shandong Province，China
por: Yuan, Haowen, et al.
Publicado: (2023)

Immunogenicity and safety of quadrivalent and 9-valent human papillomavirus vaccines in Indian clinical trial participants
por: Garland, Suzanne M., et al.
Publicado: (2022)

Human papillomavirus vaccination at the first opportunity: An overview
por: Bednarczyk, Robert A., et al.
Publicado: (2023)

Prevalence and human papillomavirus (HPV) genotype distribution in Suzhou, China
por: Wang, Tianyu, et al.
Publicado: (2023)

Resolution of Harada disease-like uveitis after quadrivalent human papillomavirus vaccination: a case report
por: Kong, Kangjie, et al.
Publicado: (2021)

Human papillomavirus vaccine effectiveness by age at vaccination: A systematic review
por: Ellingson, Mallory K., et al.
Publicado: (2023)

Barriers and facilitators in uptake of human papillomavirus vaccine across English Canada: A review
por: Khan, Amal, et al.
Publicado: (2023)

The association of initiating HPV vaccination at ages 9–10 years and up-to-date status among adolescents ages 13–17 years, 2016-2020
por: Minihan, Adair K., et al.
Publicado: (2023)

Myasthenia gravis after the third dose of human papillomavirus 9-valent vaccine: A case report
por: Ding, Yuan, et al.
Publicado: (2023)

Parents’ willingness to vaccinate their daughters with human papillomavirus vaccine and associated factors in Debretabor town, Northwest Ethiopia: A community-based cross-sectional study
por: Aragaw, Getie Mihret, et al.
Publicado: (2023)

An investigation on cervical cancer and human papillomavirus vaccine knowledge, and analysis of influencing factors for choosing domestic or imported 2vHPV vaccine among females in Shenzhen, China
por: Chen, Linxiang, et al.
Publicado: (2023)

HPV vaccine initiation at 9 or 10 years of age and better series completion by age 13 among privately and publicly insured children in the US
por: Saxena, Kunal, et al.
Publicado: (2023)

Multi-level quality improvement strategies to optimize HPV vaccination starting at the 9-year well child visit: Success stories from two private pediatric clinics
por: Zorn, Sherri, et al.
Publicado: (2023)

Safety and immunogenicity of a bivalent HPV16/18 vaccine in Chinese females
por: Shi, Li-Wei, et al.
Publicado: (2023)

Multiple infections containing the top five prevalent HPV genotypes and their impact on cervical lesions in Changzhou, China
por: Gong, Ping, et al.
Publicado: (2023)

Medical ethics principles underscore advocating for human papillomavirus vaccine
por: Healy, C. Mary, et al.
Publicado: (2022)

Human papillomavirus (HPV) vaccination intent and its associated factors: a study of ethnically diverse married women aged 27 to 45 in Malaysia, a Southeast Asian country
por: Wong, Li Ping, et al.
Publicado: (2022)

Resumption of active recommendation of the human papillomavirus vaccine in Japan and future challenges for the National Immunization Program
por: Ujiie, Mugen
Publicado: (2022)

Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: End-of-study analysis of a Phase III randomized trial
por: Einstein, Mark H, et al.
Publicado: (2014)

Social and psychological impact of HPV testing in cervical screening: a qualitative study
por: McCaffery, K, et al.
Publicado: (2006)

AN UPWARD TREND IN DNA P16INK4A METHYLATION PATTERN AND HIGH RISK HPV INFECTION ACCORDING TO THE SEVERITY OF THE CERVICAL LESION
por: Carestiato, Fernanda Nahoum, et al.
Publicado: (2013)

Engaging health plans to prioritize HPV vaccination and initiate at age 9
por: Foley, Shaylen, et al.
Publicado: (2023)

Framing of national HPV vaccine recommendations and willingness to recommend at ages 9-10
por: Kahn, Benjamin Z., et al.
Publicado: (2023)

Post-marketing surveillance study of the safety of the HPV-16/18 vaccine in Korea (2017–2021)
por: Eun, Byung-Wook, et al.
Publicado: (2023)

Optimizing timing of adolescent vaccines: Impact of initiating HPV vaccination before Tdap or meningococcal vaccination on timely completion of the HPV vaccine series
por: Kajtezovic, Sidika, et al.
Publicado: (2023)

Implementing interventions to start HPV vaccination at age 9: Using the evidence we have
por: Brandt, Heather M., et al.
Publicado: (2023)

Does HPV vaccination initiation at age 9, improve HPV initiation and vaccine series completion rates by age 13?
por: O’Leary, Sonja C., et al.
Publicado: (2023)

HPV vaccine recommendations by age: A survey of providers in federally qualified health centers
por: Lake, Paige, et al.
Publicado: (2023)

Feminized vaccine? Parents’ attitudes toward HPV vaccination of adolescents in Poland: A representative study
por: Sobierajski, Tomasz, et al.
Publicado: (2023)

Successful treatment of anogenital warts with single dose Bacillus Calmette Guerin vaccine without prior sensitization in tuberculosis endemic country: Two case report
por: Achdiat, Pati Aji, et al.
Publicado: (2023)

Willingness to get HPV vaccination among female university students in Kuwait and its relation to vaccine conspiracy beliefs
por: Alsanafi, Mariam, et al.
Publicado: (2023)

Pediatric hematology and oncology physician and nurse practitioner views of the HPV vaccine and barriers to administration
por: Miller, Meagan E., et al.
Publicado: (2023)

HPV vaccine knowledge, attitudes, and practices among New York State medical providers, dentists, and pharmacists
por: Fernandes, Annlynn, et al.
Publicado: (2023)

HPV vaccine information, knowledge, attitude, and recommendation intention among male college students in China
por: Wu, Huamei, et al.
Publicado: (2023)

How to make effective HPV vaccine recommendations starting at age 9
por: Brewer, Noel T., et al.
Publicado: (2023)

HPV prevalence and genotype distribution among women in eastern China during the Covid-19 pandemic
por: Ma, Yongmei, et al.
Publicado: (2023)

Recommending HPV vaccination at age 9 to reduce health disparities: Communication challenges and opportunities
por: Coyne-Beasley, Tamera, et al.
Publicado: (2023)

Parents’ stigmatizing beliefs about the HPV vaccine and their association with information seeking behavior and vaccination communication behaviors
por: McKenzie, Ashley Hedrick, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_522agkqu0sj3qdgrttg3aoel83